3/28
08:04 am
sldb
Solid Biosciences Inc. (NASDAQ: SLDB) had its "outperform" rating re-affirmed by analysts at William Blair.
High
Report
Solid Biosciences Inc. (NASDAQ: SLDB) had its "outperform" rating re-affirmed by analysts at William Blair.
3/27
07:15 am
sldb
Solid Biosciences to Participate at Cantor's Virtual Muscular Dystrophy Symposium [Yahoo! Finance]
Medium
Report
Solid Biosciences to Participate at Cantor's Virtual Muscular Dystrophy Symposium [Yahoo! Finance]
3/27
07:00 am
sldb
Solid Biosciences to Participate at Cantor’s Virtual Muscular Dystrophy Symposium
Medium
Report
Solid Biosciences to Participate at Cantor’s Virtual Muscular Dystrophy Symposium
3/18
03:09 pm
sldb
Solid Biosciences Inc. (NASDAQ: SLDB) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $16.00 price target on the stock.
Low
Report
Solid Biosciences Inc. (NASDAQ: SLDB) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $16.00 price target on the stock.
3/18
02:53 pm
sldb
Solid Biosciences Inc. (NASDAQ: SLDB) had its price target raised by analysts at Barclays PLC from $8.00 to $21.00. They now have an "overweight" rating on the stock.
Low
Report
Solid Biosciences Inc. (NASDAQ: SLDB) had its price target raised by analysts at Barclays PLC from $8.00 to $21.00. They now have an "overweight" rating on the stock.
3/15
08:08 am
sldb
Solid Biosciences Inc. (NASDAQ: SLDB) is now covered by analysts at Citigroup Inc.. They set a "buy" rating and a $16.00 price target on the stock.
Medium
Report
Solid Biosciences Inc. (NASDAQ: SLDB) is now covered by analysts at Citigroup Inc.. They set a "buy" rating and a $16.00 price target on the stock.
3/14
08:30 am
sldb
Solid Biosciences Inc. (NASDAQ: SLDB) was upgraded by analysts at Piper Sandler from a "neutral" rating to an "overweight" rating. They now have a $20.00 price target on the stock, up previously from $8.00.
Medium
Report
Solid Biosciences Inc. (NASDAQ: SLDB) was upgraded by analysts at Piper Sandler from a "neutral" rating to an "overweight" rating. They now have a $20.00 price target on the stock, up previously from $8.00.
3/13
01:55 pm
sldb
Catalyst announces US launch of Duchenne drug Agamree Mar. 13, 2024 1:46 PM ET By: Val Brickates Kennedy , SA News Editor [Seeking Alpha]
Low
Report
Catalyst announces US launch of Duchenne drug Agamree Mar. 13, 2024 1:46 PM ET By: Val Brickates Kennedy , SA News Editor [Seeking Alpha]
3/13
07:44 am
sldb
Solid Biosciences Provides Fourth Quarter and Full-Year 2023 Business Update and Financial Results
Medium
Report
Solid Biosciences Provides Fourth Quarter and Full-Year 2023 Business Update and Financial Results
3/7
07:16 am
sldb
Solid Biosciences Announces Licensing Agreement with Armatus Bio for the Use of AAV-SLB101, a Proprietary, Muscle-Targeted Capsid, in the Development of an RNAi Therapy to treat FSHD [Yahoo! Finance]
Low
Report
Solid Biosciences Announces Licensing Agreement with Armatus Bio for the Use of AAV-SLB101, a Proprietary, Muscle-Targeted Capsid, in the Development of an RNAi Therapy to treat FSHD [Yahoo! Finance]
3/7
07:00 am
sldb
Solid Biosciences Announces Licensing Agreement with Armatus Bio for the Use of AAV-SLB101, a Proprietary, Muscle-Targeted Capsid, in the Development of an RNAi Therapy to treat FSHD
Medium
Report
Solid Biosciences Announces Licensing Agreement with Armatus Bio for the Use of AAV-SLB101, a Proprietary, Muscle-Targeted Capsid, in the Development of an RNAi Therapy to treat FSHD
3/6
08:00 am
sldb
Solid Biosciences to Participate at Upcoming Investor Conferences
Low
Report
Solid Biosciences to Participate at Upcoming Investor Conferences
1/30
10:11 am
sldb
Muscular Dystrophy Association Announces Recipient of 2024 MDA Legacy Award for Achievement in Research, is Jeffrey Chamberlain, Ph.D., Leading Professor in Gene Therapy [Yahoo! Finance]
Low
Report
Muscular Dystrophy Association Announces Recipient of 2024 MDA Legacy Award for Achievement in Research, is Jeffrey Chamberlain, Ph.D., Leading Professor in Gene Therapy [Yahoo! Finance]
1/17
12:57 pm
sldb
Solid Biosciences' (SLDB) DMD Drug Gets Orphan Tag, Stock Up [Yahoo! Finance]
Low
Report
Solid Biosciences' (SLDB) DMD Drug Gets Orphan Tag, Stock Up [Yahoo! Finance]
1/16
08:09 am
sldb
Solid Biosciences Granted FDA Orphan Drug Designation for Duchenne Muscular Dystrophy Gene Therapy Candidate SGT-003 [Yahoo! Finance]
Medium
Report
Solid Biosciences Granted FDA Orphan Drug Designation for Duchenne Muscular Dystrophy Gene Therapy Candidate SGT-003 [Yahoo! Finance]
1/16
08:00 am
sldb
Solid Biosciences Granted FDA Orphan Drug Designation for Duchenne Muscular Dystrophy Gene Therapy Candidate SGT-003
Medium
Report
Solid Biosciences Granted FDA Orphan Drug Designation for Duchenne Muscular Dystrophy Gene Therapy Candidate SGT-003
1/15
12:27 pm
sldb
Solid Biosciences (SLDB) Rises 271% in 3 Months: Here's Why [Yahoo! Finance]
Low
Report
Solid Biosciences (SLDB) Rises 271% in 3 Months: Here's Why [Yahoo! Finance]
1/8
07:14 am
sldb
Solid Biosciences Announces $109 Million Private Placement [Yahoo! Finance]
Medium
Report
Solid Biosciences Announces $109 Million Private Placement [Yahoo! Finance]
1/8
07:09 am
sldb
Solid Biosciences Announces $109 Million Private Placement
Medium
Report
Solid Biosciences Announces $109 Million Private Placement
1/4
08:00 am
sldb
Solid Biosciences to Participate at 42nd Annual J.P. Morgan Healthcare Conference
Medium
Report
Solid Biosciences to Participate at 42nd Annual J.P. Morgan Healthcare Conference